Daoxiang Wu
机构：Sinovac Biotech
发表论文 13 篇 · 总被引 107 次 · h-index 7
代表论文
- A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera (2023 · Experimental Hematology and Oncology · 被引 34)
- Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b (2024 · British Journal of Haematology · 被引 17)
- Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa‐2b treatment in patients with polycythaemia vera (2024 · British Journal of Clinical Pharmacology · 被引 17)
- A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera (2023 · Future Oncology · 被引 13)
- Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera (2025 · Pharmacology Research & Perspectives · 被引 9)
- Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b (2024 · Frontiers in Pharmacology · 被引 7)